SCHEMBL7006136

SCHEMBL7006136

CCOC(=O)c1[nH]c(Cc2ccccc2)c(C(=O)OCC)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
ALOX5 P09917 11/20 0.50
PTGES O14684 6/20 0.48
HTT P42858 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7005248 0.84 RAB9A (0.54) RAB9ANPC1KMT2ASMN1; SMN2ALOX5
SCHEMBL11553029 0.74 ALOX5 (0.54) SMN1; SMN2ALOX5PTGESL3MBTL1KDM4E
SCHEMBL3262242 0.73 SMN1; SMN2 (0.56) RAB9ANPC1KMT2ASMN1; SMN2ALOX5
SCHEMBL7005884 0.72 ALDH1A1 (0.50) RAB9ANPC1KMT2ASMN1; SMN2HTT
SCHEMBL7826782 0.72 ALOX5 (0.81) KMT2AALOX5PTGESALDH1A1KDM4E
SCHEMBL2342953 0.71 TUBB4A (0.63) RAB9ANPC1KMT2ASMN1; SMN2HTT
SCHEMBL4701791 0.71 ALDH1A1 (0.57) RAB9ANPC1SMN1; SMN2ALOX5PTGES
SCHEMBL13495321 0.71 SMN1; SMN2 (0.53) RAB9ANPC1KMT2ASMN1; SMN2ALOX5
SCHEMBL753833 0.71 TUBB4A (0.60) RAB9ANPC1KMT2ASMN1; SMN2HTT
SCHEMBL7114817 0.71 RAB9A (0.64) RAB9ANPC1KMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363910-A2 METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2003-11-26 EP disclosed
WO-2002040486-A2 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-05-23 WO disclosed